Cite
Rico A, Ninove L, Maarouf A, et al. Determining the best window for BNT162b2 mRNA vaccination for SARS-CoV-2 in patients with multiple sclerosis receiving anti-CD20 therapy. Mult Scler J Exp Transl Clin. 2021;7(4):20552173211062142doi: 10.1177/20552173211062142.
Rico, A., Ninove, L., Maarouf, A., Boutiere, C., Durozard, P., Demortiere, S., Saba Villarroel, P. M., Amroun, A., Fourié, T., de Lamballerie, X., Pelletier, J., & Audoin, B. (2021). Determining the best window for BNT162b2 mRNA vaccination for SARS-CoV-2 in patients with multiple sclerosis receiving anti-CD20 therapy. Multiple sclerosis journal - experimental, translational and clinical, 7(4), 20552173211062142. https://doi.org/10.1177/20552173211062142
Rico, Audrey, et al. "Determining the best window for BNT162b2 mRNA vaccination for SARS-CoV-2 in patients with multiple sclerosis receiving anti-CD20 therapy." Multiple sclerosis journal - experimental, translational and clinical vol. 7,4 (2021): 20552173211062142. doi: https://doi.org/10.1177/20552173211062142
Rico A, Ninove L, Maarouf A, Boutiere C, Durozard P, Demortiere S, Saba Villarroel PM, Amroun A, Fourié T, de Lamballerie X, Pelletier J, Audoin B. Determining the best window for BNT162b2 mRNA vaccination for SARS-CoV-2 in patients with multiple sclerosis receiving anti-CD20 therapy. Mult Scler J Exp Transl Clin. 2021 Nov 29;7(4):20552173211062142. doi: 10.1177/20552173211062142. eCollection 2021 Oct. PMID: 34925877; PMCID: PMC8673883.
Copy
Download .nbib